文献速递重症综合管理与镇静镇痛心脑血管急症呼吸衰竭与机械通气

COVID-19、肺炎、心肌梗死或重症后的脑健康

Brain Health After COVID-19, Pneumonia, Myocardial Infarction, or Critical Illness.
PubMed 文献 · JAMA Netw Open · 2023-12-01
一句话结论因COVID-19住院者远期脑健康受损,但与因其他相似严重程度疾病住院者相比总体无更多损害(执行功能除外)。

该前瞻性队列研究在丹麦哥本哈根2家学术医院开展,纳入120例COVID-19住院患者、125例因肺炎、心肌梗死或非COVID-19需重症监护疾病住院的对照患者及100名健康对照,随访18个月。COVID-19患者认知状态差于健康对照(SCIP 59.0 vs 68.8;MoCA 26.5 vs 28.2),但与住院对照无差异(SCIP 61.6;MoCA 27.2)。除执行功能障碍(Trail Making Test B部分相对均值差1.15)外,COVID-19患者脑健康未比住院对照更受损。作者认为,长期脑健康关联可能并非COVID-19特有,而与整体疾病严重程度和住院相关。

要点

  • COVID-19住院者18个月随访认知差于健康对照:SCIP 59.0 vs 68.8,MoCA 26.5 vs 28.2。
  • COVID-19住院者认知与住院对照无差异:SCIP 61.6,MoCA 27.2。
  • 除执行功能障碍(相对均值差1.15,95%CI 1.01-1.31)外,COVID-19脑健康未比住院对照更受损。
  • 作者认为,长期脑健康关联可能非COVID-19特有,而与整体疾病严重程度和住院相关。

适用人群与场景

  • 2020年3月1日至2021年3月31日在哥本哈根2家学术医院因COVID-19住院的患者(120例,平均年龄60.8岁,男性70例)。
  • 2020年3月1日至2021年6月30日因肺炎、心肌梗死或非COVID-19需重症监护疾病住院的对照患者(125例,平均年龄66.0岁,男性73例)。
  • 年龄和性别匹配的健康对照(100例,平均年龄62.9岁,男性46例)。

研究设计与关键结果

  • 前瞻性队列研究,在丹麦哥本哈根2家学术医院开展,纳入345名参与者,随访18个月,评估于2021年11月1日至2023年2月28日进行。
  • 主要结局为总体认知,用精神病学认知障碍筛查(SCIP)和蒙特利尔认知评估(MoCA)评估;次要结局为执行功能、焦虑、抑郁症状和神经功能缺损。
  • COVID-19患者认知状态差于健康对照:估计平均SCIP评分59.0(95%CI 56.9-61.2)vs 68.8(95%CI 66.2-71.5);估计平均MoCA评分26.5(95%CI 26.0-27.0)vs 28.2(95%CI 27.8-28.6)。
  • COVID-19患者与住院对照认知无差异:平均SCIP评分61.6(95%CI 59.1-64.1);平均MoCA评分27.2(95%CI 26.8-27.7)。
  • COVID-19患者在所有其他精神和神经评估中也差于健康对照。
  • 除执行功能障碍(Trail Making Test B部分;相对均值差1.15,95%CI 1.01-1.31)外,COVID-19患者脑健康未比住院对照更受损。
  • 这些结果在各种敏感性分析中保持一致。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究,设匹配对照。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-19后脑健康受损,但总体不重于3个疾病严重程度相当的非COVID-19队列。
  • 作者认为,长期脑健康关联可能并非COVID-19特有,而与整体疾病严重程度和住院相关。
  • 作者认为,该信息有助于理性看待COVID-19后脑健康的担忧。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Brain health is most likely compromised after hospitalization for COVID-19; however, long-term prospective investigations with matched control cohorts and face-to-face assessments are lacking.

OBJECTIVE: To assess whether long-term cognitive, psychiatric, or neurological complications among patients hospitalized for COVID-19 differ from those among patients hospitalized for other medical conditions of similar severity and from healthy controls.

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study with matched controls was conducted at 2 academic hospitals in Copenhagen, Denmark. The case cohort comprised patients with COVID-19 hospitalized between March 1, 2020, and March 31, 2021. Control cohorts consisted of patients hospitalized for pneumonia, myocardial infarction, or non-COVID-19 intensive care-requiring illness between March 1, 2020, and June 30, 2021, and healthy age- and sex-matched individuals. The follow-up period was 18 months; participants were evaluated between November 1, 2021, and February 28, 2023.

EXPOSURES: Hospitalization for COVID-19.

MAIN OUTCOMES AND MEASURES: The primary outcome was overall cognition, assessed by the Screen for Cognitive Impairment in Psychiatry (SCIP) and the Montreal Cognitive Assessment (MoCA). Secondary outcomes were executive function, anxiety, depressive symptoms, and neurological deficits.

RESULTS: The study included 345 participants, including 120 patients with COVID-19 (mean [SD] age, 60.8 [14.4] years; 70 men [58.3%]), 125 hospitalized controls (mean [SD] age, 66.0 [12.0] years; 73 men [58.4%]), and 100 healthy controls (mean [SD] age, 62.9 [15.3] years; 46 men [46.0%]). Patients with COVID-19 had worse cognitive status than healthy controls (estimated mean SCIP score, 59.0 [95% CI, 56.9-61.2] vs 68.8 [95% CI, 66.2-71.5]; estimated mean MoCA score, 26.5 [95% CI, 26.0-27.0] vs 28.2 [95% CI, 27.8-28.6]), but not hospitalized controls (mean SCIP score, 61.6 [95% CI, 59.1-64.1]; mean MoCA score, 27.2 [95% CI, 26.8-27.7]). Patients with COVID-19 also performed worse than healthy controls during all other psychiatric and neurological assessments. However, except for executive dysfunction (Trail Making Test Part B; relative mean difference, 1.15 [95% CI, 1.01-1.31]), the brain health of patients with COVID-19 was not more impaired than among hospitalized control patients. These results remained consistent across various sensitivity analyses.

CONCLUSIONS AND RELEVANCE: This prospective cohort study suggests that post-COVID-19 brain health was impaired but, overall, no more than the brain health of patients from 3 non-COVID-19 cohorts of comparable disease severity. Long-term associations with brain health might not be specific to COVID-19 but associated with overall illness severity and hospitalization. This information is important for putting understandable concerns about brain health after COVID-19 into perspective.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Peinkhofer C, Zarifkar P, Christensen RHB, et al. Brain Health After COVID-19, Pneumonia, Myocardial Infarction, or Critical Illness. JAMA Netw Open. 2023. PMID: 38153733. doi:10.1001/jamanetworkopen.2023.49659

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。